NRx Pharmaceuticals, Inc. (NRXP)
Pre-market:
| Previous close | 1.3700 |
| Open | 1.4100 |
| Bid | 1.2900 x 100 |
| Ask | 1.3700 x 100 |
| Day's range | 1.3000 - 1.4400 |
| 52-week range | 1.3000 - 7.3300 |
| Volume | |
| Avg. volume | 79,589 |
| Market cap | 14.189M |
| Beta (5Y monthly) | 1.25 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.6800 |
| Earnings date | 11 Nov 2024 - 15 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 31.50 |
PR NewswireHOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire a Premier West Coast Interventional Psychiatric Clinic
HOPE Therapeutics, Inc., ("HOPE," the "Company"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), today announced signing a non-binding Letter of Intent (LOI) for acquisition of a premier West Coast Interventional Psychiatric Clinic. Importantly, as a component of the acquisition, the founder of the clinic, a pioneer and nationally recognized leader in the use of advanced treatments for treatment of CNS disorders, has agreed to
PR NewswireNRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100 (Ketamine)
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, ("NRx," the "Company"), today announced that twelve-month real-time stability on the first manufactured lot of NRX-100 (Ketamine) at Nephron Pharmaceuticals, utilizing commercial scale processes, was reached on September 24, 2024. In this process, no degradation of the active ingredient was observed. These findings are consistent with projected room temperature shelf stability in excess of three years. Accelera
- PR Newswire
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, ("NRx," the "Company"), today highlighted that the Company's pipeline products NRX-100 and NRX-101 were featured in an article published on Psychiatrist.com. This prominent outlet is the home of the Journal of Clinical Psychiatry, the official journal of the American Society of Clinical Psychopharmacology.
